The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). As t(4;14) uniquely results in FGFR3 expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3 and its expression was correlated with the t(4;14) status. FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14) positive cases expressed FGFR3 and 12 (92%) FGFR3 positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (p<0.0001). FGFR3 expression by immunohistochemistry was associated with the IgA isotype (p=0.0059), a shorter progression free survival (median 11.5 vs. 25.8 months, p=0.0172) and a shorter overall survival (median 19.2 vs 46.3 months, p=0.0309).
Introduction
Chromosomal translocations involving the immunoglobulin heavy chain gene (IgH) locus are found frequently in multiple myeloma (MM), a malignancy of terminally differentiated B-cells. 1, 2, 3 One of the most common translocations, t(4;14), seen in 10-20% of cases, is associated with a poor prognosis. 4, 5, 6, 7 The molecular pathogenesis of t(4;14) is thought to involve aberrant immunoglobulin class switching recombination, leading to a reciprocal translocation between chromosomes 14q32 and 4p16.3 that repositions FGFR3 to der (14) and creates a fusion gene with MMSET on der(4) under the influence of strong enhancers from the IgH region. 8, 9 For personal use only. on August 31, 2017. by guest www.bloodjournal.org From FGFR3 is one of a family of five tyrosine kinases through which fibroblast growth factors signal. These receptors are characterized by an extracellular domain with two or three immunoglobulin-like domains, a transmembrane domain and a cytoplasmic tyrosine kinase domain. On ligand binding, FGFR3 undergoes dimerization and tyrosine autophosphorylation, resulting in cell proliferation and differentiation. In MM, FGFR3 dysregulation appears to occur exclusively as a consequence of translocation. 10 We and others have demonstrated that aberrant FGFR3 expression induces lymphoid malignancies in mice, and that aberrant expression in myeloma cell lines results in cell proliferation and survival. 11, 12 Recent studies from our group suggest that the inhibition of FGFR3 by a small molecule induces differentiation and apoptosis of myeloma cell lines and primary MM cells, suggesting FGFR3 is a therapeutic target. 13, 14, 15 The t(4;14) can be detected by fluorescence in situ hybridization (FISH) or gene expression profiling, 16, 17 and FGFR3 expression has been assessed at the mRNA level by
RT-PCR. 6 However, FGFR3 protein expression, which could be a more clinically applicable diagnostic tool, has not been systematically examined. We therefore evaluated paraffin immunocytochemistry (IHC) for FGFR3 expression, and correlated its expression with t(4;14) by FISH and clinical outcome.
Study design Patients
Eight-five consecutive MM cases accessioned and diagnosed by Durie/Salmon criteria between 1999-2002 were studied. The clinical and laboratory features are summarized in 
cIg-FISH analysis
Ficoll-gradient centrifugation enriched mononuclear cells were stained by interphase FISH combined with immunofluorescent cytoplasmic light chain staining (cIg-FISH) to optimize the scoring specificity as previously described 7 .
Statistical analysis
Statistical evaluation used Fisher's exact test, chi-squire test and the nonparametric Wilcoxon test. Progression free survival (PFS) and overall survival (OS) were calculated from the transplant date by the Kaplan-Meier method. Differences between survival curves were analyzed by Log-rank test.
Results

Immunocytochemistry
Anti-CD138 stained all myeloma cells in the evaluated cases. In 13 (15%) of 85 cases, more than 50% of the myeloma cells had moderate to strong membrane and/or cytoplasmic FGFR3 immunoreactivity (Figure1A). The bone marrow hematopoietic cells were FGFR3 negative as were all 10 normal and 10 CLL bone marrow controls.
Plasma cells (<5%) from normal marrows or CLL marrows were CD138 positive but negative for FGFR3. 
Correlation of FGFR3 expression, t(4;14) and clinical features
Discussion
The t(4;14) is an independent prognostic factor in MM and, as it is predictive for an adverse outcome, a simple, robust and rapid method to detect t(4;14) would be clinically useful. In this study, we found IHC can detect FGFR3 expression in myeloma cells and is strongly correlated with t(4;14) detected by interphase cIg-FISH. To our knowledge, this is the first report of aberrant expression of FGFR3 detected by IHC in a large MM series. Furthermore, FGFR3 expression in MM is associated with the IgA isotype and a shorter OS or PFS, consistent with the features of t(4;14) detected by interphase-FISH 4, 7 In this series, 80% of the MM cases were negative for both FGFR3 expression and t(4;14), 14% were positive for both FGFR3 and t(4;14), 4.7% were negative for FGFR3 but t(4;14) positive and 1.5% were positive for FGFR3 but t(4;14) negative.
Therefore, the sensitivity of IHC is 75% and the specificity is 98% in predicting t(4;14).
We found that 25% of the t(4;14) positive cases are FGFR3 negative by IHC, in agreement with reports by Keats et al 6 and Santra et al 16 who identified 26% and 32% of their MM cases respectively lacked FGFR3 expression at mRNA level while expressing the IgH/MMSET transcript. An interstitial FGFR3 deletion could explain this finding but in this series, t(4;14) FISH analysis did not detect a FGFR3 deletion in cases lacking FGFR3 expression. Other cryptic mechanisms that block FGFR3 expression at transcriptional or translational levels may account for this discrepancy.
That 1(7.7%) of our 13 cases with FGFR3 expression was t(4;14) negative is unexpected and contrasts with a previous study in which t(4;14) were detected in all cases expressing FGFR3 at the mRNA level. 18 Although rare, it is possible that FGFR3 activation may be due to gene mutations, 19 For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
